CytomX Therapeutics Inc (NASDAQ:CTMX) Sees Significant Growth in Short Interest

CytomX Therapeutics Inc (NASDAQ:CTMX) was the recipient of a significant growth in short interest in October. As of October 31st, there was short interest totalling 1,970,000 shares, a growth of 13.2% from the September 30th total of 1,740,000 shares. Based on an average trading volume of 442,100 shares, the days-to-cover ratio is presently 4.5 days. Currently, 4.5% of the shares of the stock are short sold.

Several institutional investors have recently added to or reduced their stakes in the company. First Trust Advisors LP purchased a new stake in shares of CytomX Therapeutics during the 1st quarter valued at about $263,000. Strs Ohio raised its holdings in shares of CytomX Therapeutics by 7.5% during the 2nd quarter. Strs Ohio now owns 59,900 shares of the biotechnology company’s stock valued at $672,000 after buying an additional 4,200 shares during the period. Aperio Group LLC purchased a new stake in shares of CytomX Therapeutics during the 2nd quarter valued at about $70,000. DekaBank Deutsche Girozentrale raised its holdings in shares of CytomX Therapeutics by 64.6% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 24,200 shares of the biotechnology company’s stock valued at $257,000 after buying an additional 9,500 shares during the period. Finally, Candriam Luxembourg S.C.A. raised its holdings in shares of CytomX Therapeutics by 2.8% during the 2nd quarter. Candriam Luxembourg S.C.A. now owns 687,833 shares of the biotechnology company’s stock valued at $7,684,000 after buying an additional 19,000 shares during the period. Institutional investors own 78.74% of the company’s stock.

CytomX Therapeutics stock traded down $0.02 during trading hours on Friday, hitting $5.36. The stock had a trading volume of 354,200 shares, compared to its average volume of 536,041. The stock’s fifty day moving average is $6.76 and its two-hundred day moving average is $9.34. The stock has a market capitalization of $241.03 million, a price-to-earnings ratio of -2.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.31, a current ratio of 4.40 and a quick ratio of 4.40. CytomX Therapeutics has a 1-year low of $5.21 and a 1-year high of $19.75.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). The firm had revenue of $10.71 million during the quarter, compared to analysts’ expectations of $23.58 million. CytomX Therapeutics had a negative return on equity of 90.62% and a negative net margin of 163.18%. As a group, sell-side analysts anticipate that CytomX Therapeutics will post -1.96 EPS for the current year.

Several research firms have issued reports on CTMX. Cowen reiterated a “buy” rating on shares of CytomX Therapeutics in a research report on Wednesday, August 7th. Zacks Investment Research cut CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 15th. Nomura reissued a “buy” rating and issued a $22.00 target price on shares of CytomX Therapeutics in a report on Sunday, August 11th. ValuEngine raised CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Mizuho reissued a “buy” rating and issued a $16.00 target price on shares of CytomX Therapeutics in a report on Monday, August 12th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $18.25.

About CytomX Therapeutics

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Featured Article: Which market index is the best?

Leave a Reply

Your email address will not be published. Required fields are marked *

*